argenx SE
XBRU:ARGX
argenx SE
XBRU:ARGX
Price:
598
EUR
-2.92%
Market Closed
Market Cap:
€37B
Relative Value
The Relative Value of one
ARGX
stock under the Base Case scenario is
657.25
EUR.
Compared to the current market price of 598 EUR,
argenx SE
is
Undervalued by 9%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ARGX
Relative Value
Base Case
657.25
EUR
Undervaluation 9%
Multiples Across Competitors
ARGX Competitors Multiples
argenx SE Competitors
argenx SE Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NL |
|
argenx SE
XBRU:ARGX
|
36.5B EUR | 10.4 | 33.4 | 36.1 | 36.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.9B USD | 6 | 87.9 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190B USD | 5.1 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.3B USD | 6 | 20.6 | 12.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD | 9.6 | 29 | 21.8 | 22.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.1B USD | 5.5 | 17.5 | 12.9 | 14.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.1B AUD | 3.1 | 34.1 | 11.3 | 14.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
42.1B USD | 11.3 | 133.5 | 74.7 | 83 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
